Comorbidity,Polytherapy,and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs

Abstract

Purpose:

A high number of adverse drug reactions (ADRs), mainly caused by drug–drug interactions (DDIs), occur in neurological wards and few data are available about incidence and prevalence of DDIs in this context. This study investigated—(1) the prevalence of drug–drug and drug–disease interactions in patients admitted to a neurological unit in Italy, (2) the risk factors for DDIs, and (3) the diseases and the drug classes mostly involved in drug–drug and drug–disease interactions.

Methods:

For 2 months, we performed a retrospective, observational study in the neurological unit of St Bassiano Hospital, enrolling 79 patients who received a drug prescription at discharge.

Results:

About half of the patients were discharged with 5 or more prescribed drugs, and 72% of patients showed potential, clinically relevant DDIs. Linear correlations were observed between age and number of prescribed drugs (P < .01) and between age and number of interactions (P < .01). The number of prescribed drugs was associated with the number of detected DDIs (P < .01). The application of drug interaction alerts and the use of medication inappropriateness criteria (ie, Beers criteria) were not satisfactory in choosing the best therapy for each patient. Therefore, multidisciplinary discussions of each clinical case was required.

Conclusion:

The study demonstrated that the neurological patient, especially if elderly, has a high risk of DDI and ADRs and that many of these can be avoided by case discussion in multidisciplinary team meetings, in which the presence of a dedicated clinical pharmacist is crucial.

Keywords

neurology drug interactions clinical pharmacist potentially inappropriate medication list polypharmacy

Get full access to this article

View all access options for this article.

References

Mannesse

Derkx

de Ridder

. Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ. 1997;315(7115):1057–1058.

Mannesse

Derkx

de Ridder

. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing. 2000;29(1):35–39.

Leape

Bates

Cullen

. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274(1):35–43.

Bates

Cullen

Laird

. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29–34.

Lazarou

Pomeranz

Corey

. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.

Kohn

Corrigan

Donaldson

, eds; Institute of Medicine (US) Committee on Quality of Health Care in America. To Err is Human: Building a Safer Health System. Washington, DC: National Academy of Sciences; 2000.

Bates

Spell

Cullen

. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307–311.

May

Stewart

Cluff

. Drug interactions and multiple drug administration. Clin Pharmacol Ther. 1977;22(3):322–328.

Quinn

Day

. Clinically important drug interactions. In: Speight

Holford

Avery

, eds. Avery’s Drug Treatment. Auckland, New Zealand: Adis International; 1997; 301–308.

10.

Lenssen

Heidenreich

Schulz

. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm. 2016;38(1):119–126. doi:10.1007/s11096-015-0213-1.

11.

By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227–2246. doi:10.1111/jgs.13702.

12.

Gallagher

Ryan

Byrne

. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.

13.

Zwart-van Rijkom

Uijtendaal

ten Berg

. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68(2):187–193. doi:10.1111/j.1365-2125.2009.03443.x.

14.

Jankel

Fitterman

. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993;9(1):51–59.

15.

Egger

Drewe

Schlienger

. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58(11):773–778. doi:10.1007/s00228-002-0557-z.

16.

Pirmohamed

Orme

. Drug interactions of clinical importance. In: Davies

Ferner

de Glanville

, eds. Davies’s Textbook of Adverse Drug Reactions. London, UK: Chapman & Hall Medical; 1998: 888–912.

17.

Hauben

Zhou

. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159–186.

18.

Krahenbuhl-Melcher

Schlienger

Lampert

. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407.

19.

Leone

Magro

Moretti

. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667–675. doi:10.2165/11534400-000000000-00000.

20.

Grattagliano

Portincasa

D’Ambrosio

. Avoiding drug interactions: here’s help. J Fam Pract. 2010;59(6):322–329.

21.

Vonbach

Dubied

Krahenbuhl

. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19(6):413–420. doi:10.1016/j.ejim.2007.12.002.

22.

Pasina

Djade

Nobili

. Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf. 2013;22(10):1054–1060. doi:10.1002/pds.3510.

23.

Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60(10):E1–E25. doi:10.1111/j.1532-5415.2012.04188.x.

24.

Holland

Desborough

Goodyer

. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65(3):303–316.

25.

Kaboli

Hoth

McClimon

. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955–964.

26.

Hanlon

Lindblad

Gray

. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother. 2004;2(1):3–13.

27.

Westerlund

Marklund

. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. J Clin Pharm Ther. 2009;34(2):319–327. doi:10.1111/j.1365-2710.2008.01017.x.

28.

Marengoni

Pasina

Concoreggi

. Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med. 2014;25(9):843–846. doi:10.1016/j.ejim.2014.10.001.

29.

Thuermann

Windecker

Steffen

. Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach. Drug Saf. 2002;25(10):713–724.

30.

Zaal

Jansen

Duisenberg-van Essenberg

. Identification of drug-related problems by a clinical pharmacist in addition to computerized alerts. Int J Clin Pharm. 2013;35(5):753–762. doi:10.1007/s11096-013-9798-4.

31.

Drug Interactions Checker. Drugs.com, USA. http://www.drugs.com/drug_interactions.html. (Accessed April, 2016).

32.

Carnovale

Venegoni

Clementi

. Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment. JAMA Intern Med. 2014;174(7):1031–1032. doi:10.1001/jamainternmed.2014.1427.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.30 MB